This report suggests that advanced prostate cancer may be newly diagnosed after holmium laser enucleation of the prostate. Even if prostate cancer had not been demonstrated in the enucleated specimen, and postoperative PSA levels were below the standard values, physicians should regularly monitor ...
Immunohistochemical examination of the initial biopsy specimens revealed that 4 and 3 cases were positive for CEA and chromogranin A, respectively. In advanced prostate cancer patients with low PSA level, those markers may aid in the follow up of disease. 展开 ...
PSA 90 ng/mL; Hb 9.4 g/dL; ANC 1.5 Liver function tests continue to be abnormal Diagnosis of Recurrence Patient is diagnosed with biochemical recurrence of prostate cancer with high-volume castration-sensitive metastatic disease Germline genetic testing is negative Treatment for Recurrence ...
Metastatic prostate cancer is considered to be incurable. But now a pilot trial, in 20 selected men with early-stage metastatic prostate cancer, has shown that aggressive multimodality treatment with hormone therapy, surgery, and radiation "can eliminate detectable disease." Overall, 20% of the pat...
AbstractProstate-specific antigen (PSA) is well known as a specific tumor marker for prostate cancer, but carcinoembryonic antigen (CEA)- and carbohydrate antigen 19-9 (CA19-9)-elevating adenocarcinomas originating in the prostate gland are rare. We report a case of metastatic adenocarcinoma of th...
Meaning In patients with prostate cancer, bone metastatic burden and metastasis location may be useful in predicting survival benefit from prostate RT. Abstract Importance Prostate radiotherapy (RT) improves survival in men with low-burden metastatic prostate cancer. However, owing to the dichotomized ...
In addition to active Stat3 immunostaining, prostate cancer metastases sections were immunostained for PSA to verify the location of prostate cancer cells within the metastases-containing tissues. Parallel sections were stained with normal rabbit serum as a negative control (data not shown). ...
Our results suggest an association between lower facility-level PSA screening rates and higher metastatic prostate cancer incidence rates, which may implicate PSA screening behaviors in subsequent metastatic prostate cancer incidence. This would be consistent with findings from the ERSPC trial,2 which demo...
CTC = circulating tumour cell; mCRPC = metastatic castration-resistant prostate cancer; PSA = prostate-specific antigen. 3.2.1. PSA A total of 59 respondents (55.7%) reported that PSA was a useful/very useful biomarker for monitoring response to treatment (Table 2). We asked participants to ...
PSA 90 ng/mL; Hb 9.4 g/dL; ANC 1.5 Liver function tests continue to be abnormal Diagnosis of Recurrence Patient is diagnosed with biochemical recurrence of prostate cancer with high-volume castration-sensitive metastatic disease Germline genetic testing is negative Treatment for Recurrence ...